The Alzheimer's prevention initiative composite cognitive test score: Sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers

Journal of Clinical Psychiatry

Volumn 75, Issue 6, 2014, Pages 652-660

  Ayutyanont, Napatkamon ^a,c   Langbaum, Jessica B S ^a,c   Hendrix, Suzanne B ^f   Chen, Kewei ^a,c,d   Fleisher, Adam S ^a,c,g   Friesenhahn, Michel ^h   Ward, Michael ^h   Aguirre, Camilo ⁱ   Acosta Baena, Natalia ⁱ   Madrigal, Lucìa ⁱ   Muñoz, Claudia ⁱ   Tirado, Victoria ⁱ   Moreno, Sonia ⁱ   Tariot, Pierre N ^a,c,e   Lopera, Francisco ⁱ   Reiman, Eric M ^a,b,c,e  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f Pentara Corporation   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Baculovirus expression group   (United States)

ⁱ UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

PRESENILIN 1;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL RESEARCH; COGNITION; CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMER'S DISEASE BOSTON NAMING TEST; CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMER'S DISEASE CONSTRUCTIONAL PRAXIS AND RAVEN'S PROGRESSIVE MATRICES; CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMER'S DISEASE WORD LIST RECALL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; MINI MENTAL STATE EXAMINATION ORIENTATION TO TIME; NEUROPSYCHOLOGICAL TEST; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SAMPLE SIZE; SCORING SYSTEM; TIME PERCEPTION; TREATMENT DURATION; TREATMENT RESPONSE; WORD LIST RECALL;

ADULT; ALLELES; ALZHEIMER DISEASE; CHROMOSOME ABERRATIONS; COHORT STUDIES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; GENES, DOMINANT; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE DETECTION; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PRESENILIN-1; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS;

EID: 84903539808     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08927     Document Type: Article

References (41)

1. Reiman EM, Langbaum JBS, Tariot PN. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers Med. 2010;4(1):3-14. doi: 10.217/bm.09.91 PubMed
2. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(suppl 3):321-329. PubMed
3. Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013;169(10):737-743. doi: 10.1016/j.neurol.2013.07.017 PubMed
4. Sperling R, Donohue M, Aisen P. The A4 Trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease. Alzheimers Dement. 2012;8(4):P425-P426. doi: 10.1016/j.jalz.2012.05.134
5. Roses AD, Lutz MW, Amrine-Madsen H, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 2010;10(5):375-384. doi: 10.1038/tpj.209.69 PubMed
6. DeKosky ST. Maintaining adherence and retention in dementia prevention trials. Neurology. 2006;67(suppl 3):S14-S16. doi: 10.1212/WNL.67.9supl3.S14 PubMed (Pubitemid 44684672)
7. Martin BK, Szekely C, Brandt J, et al; ADAPT Research Group. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65(7):896-905. doi: 10.101/archneur.208.65.7.nct706 PubMed
8. Silverberg NB, Ryan LM, Carrillo MC, et al. Assessment of cognition in early dementia. Alzheimers Dement. 2011;7(3):e60-e76. doi: 10.1016/j.jalz.201. 05.01 PubMed
9. Cano SJ, Posner HB, Moline ML, et al. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry. 2010;81(12):1363-1368. doi: 10.136/jnp.209.20408 PubMed
10. Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011;76(3):280-286. doi: 10.1212/WNL.0b013e318207b1b9 PubMed
11. Elias MF, Beiser A, Wolf PA, et al. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57(6):808-813. doi: 10.101/archneur.57.6.808 PubMed (Pubitemid 30397182)
12. Saxton J, Lopez OL, Ratcliff G, et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004;63(12):2341-2347. doi: 10.1212/01.WNL.0147470.58328.50 PubMed (Pubitemid 40024347)
13. Johnson DK, Storandt M, Morris JC, et al. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol. 2009;66(10):1254-1259. doi: 10.101/archneurol.209.158 PubMed
14. Wilson RS, Leurgans SE, Boyle PA, et al. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol. 2011;68(3):351-356. doi: 10.101/archneurol.201.31 PubMed
15. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64(5):492-498. doi: 10.102/ana.21509 PubMed
16. Grober E, Hall CB, Lipton RB, et al. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc. 2008;14(2):266-278. PubMed
17. Small BJ, Bäckman L. Longitudinal trajectories of cognitive change in preclinical Alzheimer's disease: a growth mixture modeling analysis. Cortex. 2007;43(7):826-834. doi: 10.1016/S010-9452(08)70682-8 PubMed (Pubitemid 47517036)
18. Stonnington CM, Chen K, Lee W, et al. Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimers Dement. 2014;10(1):e1-e8. PubMed
19. Pike KE, Ellis KA, Villemagne VL, et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia. 2011;49(9):2384-2390. doi: 10.1016/j.neuropsychologia.201.04.012 PubMed
20. Ellis KA, Lim YY, Harrington K, et al; AIBL Research Group. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β. J Alzheimers Dis. 2013;34(4):861-871. PubMed
21. Lim YY, Maruff P, Pietrzak RH, et al; AIBL Research Group. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain. 2014;137(pt 1):221-231. PubMed
22. Sperling RA, Johnson KA, Doraiswamy PM, et al; AV45-A05 Study Group. Amyloid deposition detected with florbetapir F 18 ([18]F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013;34(3):822-831. doi: 10.1016/j.neurobiolaging.2012.06.014 PubMed
23. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 2011;10(3):213-220. doi: 10.1016/S1474-42(10)70323-9 PubMed
24. Hendrix SB. Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. Alzheimers Res Ther. 2012;4(4):24. doi: 10.186/alzrt127 PubMed
25. Crane PK, Carle A, Gibbons LE, et al; Alzheimer's Disease Neuroimaging Initiative. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6(4):502-516. doi: 10.107/s1682-012-9186-z PubMed
26. Gibbons LE, Carle AC, Mackin RS, et al; Alzheimer's Disease Neuroimaging Initiative. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6(4):517-527. doi: 10.107/s1682-012-9176-1 PubMed
27. Dowling NM, Hermann B, La Rue A, et al. Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology. 2010;24(6):742-756. doi: 10.1037/a020176 PubMed
28. Hayden KM, Kuchibhatla M, Romero HR, et al. Pre-clinical cognitive phenotypes for Alzheimer Disease: a latent profile approach [published online ahead of print September 27, 2013]. Am J Geriatr Psychiatry. doi: 10.1016/j.jagp.2013.07.08 PubMed
29. Balsis S, Unger AA, Benge JF, et al. Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores. Alzheimers Dement. 2012;8(4): 288-294. doi: 10.1016/j.jalz.201.05.2409 PubMed
30. Xiong C, van Belle G, Chen K, et al. Combining multiple markers to improve the longitudinal rate of progression-application to clinical trials on the early stage of Alzheimer's disease. Stat Biopharm Res. 2013;5(1):54-66. doi: 10.1080/1946315.2012.7562 PubMed
31. Reiman EM, Langbaum JBS. Brain imaging in the evaluation of putative Alzheimer's disease slowing, risk-reducing and prevention therapies. In: Jagust WJ, D'Esposito M, eds. Imaging the Aging Brain. New York, NY: Oxford University Press; 2009:319-350. doi: 10.1093/acprof:oso/978019532875.03.020
32. Reiman EM, Langbaum JBS, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. In: Ashford JW, ed. Handbook of Imaging the Alzheimer Brain. Amsterdam, the Netherlands: IOS Press; 2011.
33. Ayutyanont N, Lopera F, Hendrix S, et al. Composite cognitive endpoints with improved power to detect presymptomatic Alzheimer's disease treatment effects: findings in the Colombian kindred with the E280A presenilin 1 mutation and the Alzheimer's Prevention Initiative. Alzheimers Dement. 2011;7(4):S608. doi: 10.1016/j.jalz.201.05.1729
34. Lopera F, Ardilla A, Martínez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997;277(10):793-799. doi: 10.101/jama.197.0354034027028 PubMed (Pubitemid 27111314)
35. Arango Lasprilla JC, Iglesias J, Lopera F. Neuropsychological study of familial Alzheimer's disease caused by mutation E280A in the presenilin 1 gene. Am J Alzheimers Dis Other Demen. 2003;18(3):137-146. doi: 10.17/153175030180306 PubMed (Pubitemid 36693297)
36. Rosselli MC, Ardila AC, Moreno SC, et al. Cognitive decline in patients with familial Alzheimer's disease associated with E280a presenilin-1 mutation: a longitudinal study. J Clin Exp Neuropsychol. 2000;22(4): 483-495. doi: 10.1076/1380-395(208)2:4;1-0;FT483 PubMed
37. Food and Drug Administration. Guidance for industry Alzheimer's disease: Developing drugs for the treatment of early stage disease. Draft Guidance, 2013. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. Updated January 16, 2013. Accessed March 10, 2014.
38. Langbaum JB, Hendrix SB, Ayutyanont N, et al. An empirically derived composite cognitive endpoint with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement. In press.
39. Riley KP, Jicha GA, Davis D, et al. Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis. 2011;25(4):707-717. PubMed
40. Wilson RS, Li Y, Bienias JL, et al. Cognitive decline in old age: separating retest effects from the effects of growing older. Psychol Aging. 2006;21(4): 774-789. doi: 10.1037/082-7974.21.4.74 PubMed (Pubitemid 46052827)
41. Bateman RJ, Xiong C, Benzinger TL, et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. doi: 10.1056